Sg III Inhibitors
Sg III inhibitors represent a class of chemicals that interfere with the Sg III protein and its related cellular functions by targeting various biochemical pathways. These compounds are not necessarily direct antagonists of the Sg III protein but act by modulating the signaling cascades that govern the protein's activity. The chemicals listed range from morpholine derivatives, like LY294002, to macrolide compounds such as rapamycin, each with distinct mechanisms of action but a unifying purpose of attenuating the function of Sg III by means of pathway interference.
Among the chemicals, some target the PI3K/Akt/mTOR signaling axis, which is a critical regulator of cell growth, proliferation, and survival. Inhibitors exert their effects by binding to the catalytic subunit of PI3K, thereby preventing the activation of downstream molecules such as Akt and subsequently mTOR. This results in a cascade effect that can suppress Sg III activity if it is a downstream effector. The diversity of these chemicals reflects the complexity of cellular signaling and the myriad ways in which a protein's activity can be controlled. By targeting different kinases and enzymes that are upstream of Sg III, these inhibitors can indirectly reduce the activity of Sg III through a ripple effect within the cell's signaling networks. Each inhibitor's action underscores the interconnected nature of cellular processes and the potential for multiple points of intervention in the modulation of a protein's activity. These inhibitors, by virtue of their actions on various signaling pathways, provide a toolkit for modulating Sg III activity through indirect means.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a morpholine derivative that acts as a potent inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K can disrupt downstream signaling pathways which Sg III may be a part of, leading to reduced activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal metabolite that selectively inhibits PI3K. By blocking PI3K activity, it may interfere with Sg III signaling cascades that depend on PI3K-mediated phosphorylation events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a macrolide compound that inhibits the mTOR pathway, which is often linked to PI3K/Akt signaling. Through this inhibition, it can indirectly affect Sg III function within these interconnected pathways. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an AKT inhibitor that impedes AKT phosphorylation and activation. Given that AKT is a downstream target of PI3K, its inhibition can reduce the activation of Sg III if it is downstream of AKT. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that prevents the activation of the MAPK/ERK pathway. By doing so, it may indirectly inhibit Sg III activity if Sg III is part of the MAPK-regulated processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. If Sg III activity is modulated through p38 MAPK signaling, this inhibition may reduce Sg III function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a broad-spectrum inhibitor of c-Jun N-terminal kinase (JNK). Its use may result in the downregulation of Sg III activity if Sg III is responsive to JNK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If Sg III function is related to Src kinase signaling, dasatinib’s inhibition of this pathway can lead to decreased Sg III activity. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL and other kinases. If Sg III is influenced by these kinases, imatinib could inhibit its function indirectly. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
Apigenin is a flavone that has been shown to inhibit protein kinase C. If Sg III is regulated by or associated with the PKC pathway, apigenin could lead to a decrease in Sg III activity. | ||||||